Genflow Biosciences Share Discussion Threads

[iammrweald] 02/2/2024 09:26

Er,maybe those who walk among you bearing false gifts may have something to the " just added!" latest spike,drop? Hmmmmm
Oh,could you smash BP share price for me,or even RB? I'd like to add! he he

[luckyabbeygale] 02/2/2024 08:40

Derampers killing this share. Well it won't be for long.

[luckyabbeygale] 02/2/2024 08:27

I can do anything to a share price of any company thanks to YouTube.

[luckyabbeygale] 01/2/2024 23:35

Science rejuvenates woman's skin cells to 30 years younger video on YouTube that was on the bbc a year ago. I believe is has something to do with Genflow. People will be paying out billions for Genflow's technology in the future. Imagine what would happen if I put it on every YouTube channel about Genflow.

[northeast14] 01/2/2024 17:39

Not what I was expecting today at all. Strong plans for the year ahead and key milestones for the company. Seems like you can’t buy in volume but can sell. Maybe an order being worked in the background. All very odd

[luckyabbeygale] 01/2/2024 09:56

On IG sharedeal they now want 1.9p for just £2,500 worth.

[pie chart] 01/2/2024 07:28

Nice work Eric and team. GLA all who have held strong. This is a solid update and shows we are taking a multifaceted approach to the development and growth of the company.

[northeast14] 01/2/2024 07:23

Great to see all them people sing out lately. What a fantastic RNS! Huge progress being made!!

[moneymunch] 01/2/2024 07:03

RNS Number : 4088B
Genflow Biosciences PLC
01 February 2024


1 February 2024



Genflow Biosciences Plc



("Genflow" or "the Company")



Genflow Biosciences Releases 2023 Year-End Review and Highlights Key Priorities for 2024



The Company (LSE:GNF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics that potentially halt or slow the ageing process, is pleased to provide a year-end review and summary of its progress during 2023 and defined strategic priorities for 2024.



The Company achieved many significant accomplishments throughout the year across all aspects of its business. The full year-end review can be viewed on Genflow's website: hxxps://genflowbio.com/genflow-biosciences-plc-2023-year-in-review/.



Key 2023 Highlights:



· Genflow expanded its intellectual property portfolio with a provisional patent application for editing the SIRT6 gene, linked to longevity and age-related diseases.



· Began trading on the OTCQB Venture Market in the US under the ticker GENFF, aligned to its US-focused strategy.



· Genflow received positive feedback from the Federal Agency for Medicines and Health Products in Belgium on the design of Phase I/II clinical trials for its lead drug candidate, GF-1002, in NASH patients.



· Genflow made several key appointments, including Capital Plus Partners Ltd as Joint Broker in order to access both institutional and international investment; Harbor Access for investor relations support; and Prof. Dr. Sven Francque, an expert in nonalcoholic fatty liver disease and Prof. Dr. Mary E. Rinella, a fatty liver disease specialist to its Scientific Advisory Board.



Strategic Priorities in 2024:



· Genflow awarded 2.89 million Euros in two new grants that will broaden its research pipeline and expand the size of its therapeutic markets over the next three years. (Refer to press release:



· Genflow to undertake key Investigational New Drug (IND)-enabling development activities that will help define the pharmacological and toxicological properties of its lead drug candidate, GF-1002, and its potential benefits for NASH patients.



· Initial site selection and QMS framework for clinical readiness, expected by the end of 2025 for the NASH program.



· Commence preliminary discussions with the European Medicines Agency (EMA) on Mechanism of Action (MoA) data for Orphan Drug Application (ODA) for our second compound GF-3001, targeting Werner Syndrome.



· Select Contract Development and Manufacturing Organization (CDMO) for advancing the GMP manufacturing of the NASH clinical lot of lead drug candidate, GF-1002.



· Develop and implement project management, budgeting and governance for collaborative partners, in line with clinical and pre-clinal activities that will enable IND applications.



· Moving key patent applications under the Patent Cooperation Treaty (PCT) to the national phase, while further expanding our development pipeline with new products and new indications.



Dr. Eric Leire, CEO of Genflow commented: "The milestones we reached in 2023 were numerous, and I commend our team for their exceptional commitment to execution and delivery. While 2023 was a pivotal year, we're poised for an even stronger 2024, as we shift focus to scaling development of our lead drug candidate, GF-1002, and its potential benefits for NASH patients. With the support of our partners and the backing of new grants, we are poised to make meaningful advancements in the field of longevity."

[moneymunch] 31/1/2024 22:38

Too many punters have sold their shares too cheaply, me thinks..
Gla holders...On and UP!!! :-)

[bri15] 31/1/2024 12:23

The Guardian financial section named Genflow as one of the firms to watch in 2024,well don't just watch, I'd advise you to get in before the crazy share price rise.

[logica2me] 31/1/2024 12:04

Looking good today this.

[bri15] 31/1/2024 11:55

Something is up for the ASK to be rising on sells.

[bri15] 31/1/2024 11:53

Massive rise coming here,so undervalued this one.

[moneymunch] 31/1/2024 11:22

On and UP!!! Gla holders:-)

[luckyabbeygale] 31/1/2024 11:17

1.9299p for £15,000 they now want.
Going by this my holding is now back in profit.

[moneymunch] 30/1/2024 12:49

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,457 followers

46m

2-5% of all Americans have NASH (Non-Alcoholic Steatohepatitis) - and these rates are rising. Understanding the disease and its treatment is vital to curtailing its impact on public health. Read more about the disease's rise and what is being done to treat it here:

#NASH #livertreatment #GenflowBiosciences #GENF #GENFF

[bri15] 30/1/2024 12:15

Off topic,Echo energy going to flying this afternoon.

[bri15] 30/1/2024 11:43

NT to buy and can sell all my holding straight off, something big coming, hopefully.

[bri15] 30/1/2024 11:22

Buys,buys and more buys, happy days returning hopefully 😁

[bri15] 30/1/2024 11:19

SP about to blow!

[moneymunch] 30/1/2024 11:02

An absolute steel at current low with potential significant news at anytime!!! Gla holders, Genflow is still set for a great year ahead imho. :-)

[northeast14] 29/1/2024 12:48

Yes absolutely ridiculous